GlassScriptPhysician profile
Jonathan H Smeltzer
NPI 1578826590
$10,241.42
in general payments reported to CMS, 2019-2025
49 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,238 · 2020: $532 · 2021: $1,579 · 2022: $1,602 · 2023: $1,602 · 2024: $1,374 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,272.19 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,732.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,415.31 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,020.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $954.32 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $621.77 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $452.04 | 2019-2024 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.90 | 2019-2025 | Jardiance |
| Abbott Laboratories | $408.62 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $337.09 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $282.32 | 2019-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.26 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $212.63 | 2019-2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $175.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Daiichi Sankyo INC. | $155.80 | 2019-2023 | Injectafer |
| Amarin Pharma, INC. | $154.71 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Smeltzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.